ASX:CYC Cyclopharm (CYC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cyclopharm Stock (ASX:CYC) 30 days 90 days 365 days Advanced Chart Get Cyclopharm alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume10,000 shsAverage VolumeN/AMarket CapitalizationA$219.50 millionP/E RatioN/ADividend Yield0.74%Price TargetN/AConsensus RatingN/A Company Overview Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia. Read More Receive CYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address CYC Stock News HeadlinesCyclopharm Limited Secures Shareholder Approval for Key Resolutions at AGMMay 29, 2025 | tipranks.comCyclopharm Limited Expands US Market Presence with Technegas™May 29, 2025 | tipranks.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.July 18 at 2:00 AM | Timothy Sykes (Ad)Cyclopharm Achieves Record Sales with US Expansion in 2024May 29, 2025 | tipranks.comCyclopharm Limited Releases Cautious Financial ProjectionsMay 29, 2025 | tipranks.comCyclopharm Limited Announces 2025 Annual General MeetingApril 29, 2025 | tipranks.comCyclopharm to Present at NWR Virtual Healthcare ConferenceMarch 18, 2025 | tipranks.comCyclopharm to Provide Key Business Update on March 19, 2025March 16, 2025 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:CYC CIKN/A Webwww.cyclopharm.com.au Phone61 2 9541 0411FaxN/AEmployees87Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$9.32 million Net Margins-40.69% Pretax MarginN/A Return on Equity-23.34% Return on Assets-15.37% Debt Debt-to-Equity Ratio11.72 Current Ratio4.38 Quick Ratio4.68 Sales & Book Value Annual SalesA$24.06 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.40 Book ValueA$0.50 per share Price / BookN/AMiscellaneous Outstanding Shares111,140,000Free FloatN/AMarket CapA$219.50 million OptionableNot Optionable Beta0.70 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (ASX:CYC) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.